EDAP vs SRDX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDAP is a StrongBuy and SRDX is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDAP’s FA Score shows that 0 FA rating(s) are green whileSRDX’s FA Score has 0 green FA rating(s).
- EDAP’s FA Score: 0 green, 5 red.
- SRDX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDAP’s TA Score shows that 6 TA indicator(s) are bullish while SRDX’s TA Score has 5 bullish TA indicator(s).
- EDAP’s TA Score: 6 bullish, 2 bearish.
- SRDX’s TA Score: 5 bullish, 2 bearish.
Price Growth
EDAP (@Medical Distributors) experienced а +24.43% price change this week, while SRDX (@Medical Specialties) price change was +1.92% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was +3.39%. For the same industry, the average monthly price growth was -5.42%, and the average quarterly price growth was -10.98%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +3.05%. For the same industry, the average monthly price growth was -8.45%, and the average quarterly price growth was -3.85%.
Reported Earning Dates
EDAP is expected to report earnings on Aug 20, 2025.
SRDX is expected to report earnings on Jul 30, 2025.
Industries' Descriptions
@Medical Distributors (+3.39% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
@Medical Specialties (+3.05% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| EDAP | SRDX | EDAP / SRDX | |
| Capitalization | 282M | 397M | 71% |
| EBITDA | -18.39M | 22.1M | -83% |
| Gain YTD | -26.244 | -27.576 | 95% |
| P/E Ratio | 100.00 | 71.51 | 140% |
| Revenue | 60.4M | 138M | 44% |
| Total Cash | 43.5M | 35.2M | 124% |
| Total Debt | 8.42M | 33.9M | 25% |
EDAP | SRDX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 2 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 91 | |
PRICE GROWTH RATING 1..100 | 94 | 62 | |
P/E GROWTH RATING 1..100 | 100 | 92 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SRDX's Valuation (91) in the Medical Specialties industry is in the same range as EDAP (98) in the Biotechnology industry. This means that SRDX’s stock grew similarly to EDAP’s over the last 12 months.
SRDX's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as EDAP (100) in the Biotechnology industry. This means that SRDX’s stock grew similarly to EDAP’s over the last 12 months.
SRDX's SMR Rating (91) in the Medical Specialties industry is in the same range as EDAP (94) in the Biotechnology industry. This means that SRDX’s stock grew similarly to EDAP’s over the last 12 months.
SRDX's Price Growth Rating (62) in the Medical Specialties industry is in the same range as EDAP (94) in the Biotechnology industry. This means that SRDX’s stock grew similarly to EDAP’s over the last 12 months.
SRDX's P/E Growth Rating (92) in the Medical Specialties industry is in the same range as EDAP (100) in the Biotechnology industry. This means that SRDX’s stock grew similarly to EDAP’s over the last 12 months.
| EDAP | SRDX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 67% | 1 day ago 70% |
| Stochastic ODDS (%) | 1 day ago 63% | 1 day ago 72% |
| Momentum ODDS (%) | 1 day ago 74% | 1 day ago 75% |
| MACD ODDS (%) | 1 day ago 67% | 1 day ago 69% |
| TrendWeek ODDS (%) | 1 day ago 75% | 1 day ago 69% |
| TrendMonth ODDS (%) | 1 day ago 84% | 1 day ago 70% |
| Advances ODDS (%) | 1 day ago 75% | 1 day ago 68% |
| Declines ODDS (%) | 9 days ago 82% | 8 days ago 69% |
| BollingerBands ODDS (%) | 1 day ago 79% | 1 day ago 78% |
| Aroon ODDS (%) | 1 day ago 85% | N/A |
EDAP and
Correlation & Price change
A.I.dvisor tells us that EDAP and AORT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EDAP and AORT's prices will move in lockstep.
| Ticker / NAME | Correlation To EDAP | 1D Price Change % | ||
|---|---|---|---|---|
| EDAP | 100% | +10.88% | ||
| AORT - EDAP | 29% Poorly correlated | +2.19% | ||
| ENZ - EDAP | 21% Poorly correlated | N/A | ||
| AVNS - EDAP | 21% Poorly correlated | +1.30% | ||
| SRDX - EDAP | 21% Poorly correlated | +0.24% | ||
| UFPT - EDAP | 20% Poorly correlated | +0.91% | ||
More | ||||
SRDX and
Correlation & Price change
A.I.dvisor tells us that SRDX and RMD have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SRDX and RMD's prices will move in lockstep.
| Ticker / NAME | Correlation To SRDX | 1D Price Change % | ||
|---|---|---|---|---|
| SRDX | 100% | +0.24% | ||
| RMD - SRDX | 32% Poorly correlated | +0.17% | ||
| UFPT - SRDX | 27% Poorly correlated | +0.91% | ||
| PRCT - SRDX | 27% Poorly correlated | +5.59% | ||
| MBOT - SRDX | 26% Poorly correlated | +1.46% | ||
| VNRX - SRDX | 26% Poorly correlated | N/A | ||
More | ||||